Evaluation of a novel 177 Lu-labelled therapeutic Affibody molecule with a deimmunized ABD domain and improved biodistribution profile

• Published in: European journal of nuclear medicine and molecular imaging Vol. 51; no. 13; p. 4038
• Main Authors: Liu, Yongsheng, Oroujeni, Maryam, Liao, Yunqi, Vorobyeva, Anzhelika, Bodenko, Vitalina, Orlova, Anna, Konijnenberg, Mark, Carlqvist, Matilda, Wahlberg, Elisabet, Loftenius, Annika, Frejd, Fredrik Y, Tolmachev, Vladimir
• Format: Journal Article
• Language: English
• Published: Germany 01.11.2024
• Subjects: Albumins - chemistry; Animals; Cell Line, Tumor; Female; Humans; Isotope Labeling; Lutetium - therapeutic use; Mice; Protein Domains; Radioisotopes - chemistry; Radioisotopes - therapeutic use; Radiopharmaceuticals - pharmacokinetics; Radiopharmaceuticals - therapeutic use; Receptor, ErbB-2 - immunology; Receptor, ErbB-2 - metabolism; Recombinant Fusion Proteins - chemistry; Recombinant Fusion Proteins - pharmacokinetics; Recombinant Fusion Proteins - pharmacology; Tissue Distribution; Therapy; Affibody molecules; Albumin binding domain; Lutetium-177

Fusion of Affibody molecules with an albumin-binding domain (ABD) provides targeting agents, which are suitable for radionuclide therapy. To facilitate clinical translation, the low immunogenic potential of such constructs with targeting properties conserved is required. The HER2-targeting Affibody...